PKI - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2019 PerkinElmer’s Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference may be recorded. [Operator Instructions]

to conference like speaker to now Mr. today, would turn over the your I President Relations. of Vice Kipp, Bryan Investor Please go ahead, sir.

Bryan Kipp

earnings Thanks, Catherine. quarter call. XXXX fourth the to conference Good afternoon, and and full welcome PerkinElmer year

call me Jamey and Vice are With Senior the Prahlad President Executive Mock, Financial and Chief and Singh, President Officer; Chief Officer. on

call get live at not Investors section the will received have our www.perkinelmer.com. you on until from note, copy of our webcast earnings February our one website is press be archived If XX, a release, and Please this you being may website of XXXX.

made begin, to earlier our we statements, statements other earnings intentions. Before in afternoon expectations, on be not may of are but we in that issued comments objectives, release those which include, need filings. this the statements the limited call Safe to projections forward-looking necessarily or Company's SEC Harbor press plans, outlined and this or everyone financial may of have or we also remind our Statements

forward-looking matters any results as from detail suggested in in which any filings. today SEC may Any views change. even if only future, discussed made the in to or our update The of our those represent disclaim to We projected certain differ by Company's actual statements are today. statements risks These statements variety obligation of forward-looking significantly due our estimates a factors, and forward-looking uncertainties. involve

of not the as as any forward-looking rely any our should today. of on So, after you views today's representing date statements

GAAP the to non-GAAP use referring earnings that during attachment in use plan promptly. press financial available to financial attachment, is comparable A are call, that release. financial our of will during the the measures. measures as not GAAP will we reconciliations directly extent to reconciled to be provide this we measures To non-GAAP this call non-GAAP an we certain most we During this call to measures reconciliation

Officer Executive Singh. and to the Prahlad? pleased I am of introduce PerkinElmer, President Chief now Prahlad

Prahlad Singh

Bryan, and evening, good everyone. you, Thank

revenue pleased the fourth per I'm increasing strong previous year-over-year a reported line X% top in the PerkinElmer both XXXX with XX%, earnings bottom and that report our quarter of beating adjusted to guidance. had share growing finish to and

fourth X%, our representing $XXX Our adjusted was million earnings share quarter and was $X.XX. growth of the per organic in revenue

As over I transformation reflect these quarters and we as to accelerate an rapid growth positive position the put on and coming organization to us beyond. become made XXXX, apparent doubt advance world has the the outcomes I stakeholders that increasingly excellent years. an changes external no XXXX have around and profitable in in will

a expansion, margin businesses, performance our discuss From macro financial evolving in XXXX our and earnings XXX in will basis adjusted XX% points organic perspective, headwinds. of per Jamey we share strong We results greater growth growth. delivered delivered across detail. a financial X%, despite of

end that markets you are and leverage to think teams, last R&D we across workflow empowering our we customers our our to familiar, to leaders our and customer address the aligned the our commercial to capabilities differently of decisions full As closer summer, needs. combined team evolving make breadth and go-to-market regional develop R&D solutions serve encouraging approach

meeting our for XXXX extremely proud has leverage I'm to all All-in-all, that XX,XXX of organization to our enter environment. new, the We their differentiated positive opportunity highly employees and a significant accelerate as capabilities people commitment outcomes for enthusiasm of collaborative of betterment needs our of and and come innovation our healthier around of day our the transformative innovating focus strong a relentless to mission operational a with customers. changing ever every who work to excellence world, on

off. our efforts fourth where pay quarter a transformation seen just few share the I'll examples from we’ve

customers impacting on milestones our by and us enabled healthcare achieve to of the focus future working critical targeted and with Our solving new issues partners. science

GSP our PerkinElmer’s gene Neonatal for Within first approach, the and of is by newborns kit diagnostics muscular available a kit screening affected for specifically Creatine FDA has analysis. then DMD for with to assay is the newborns Duchenne testing resulted using commercially two-tier and dystrophy. CK-MM screening in Kinase-MM cost way business, effective screen designed assay the approval a DMD

Screening patients their for go diagnostic it newborns that families unnecessary for ensures odyssey, from not an only but could DMD prevents otherwise also disease treatment timely undetected and a years.

Duchenne. program proprietary participating screen babies, aims to DMD is Dystrophy’s York period. screen over pilot York of kit, Muscular a state in PerkinElmer each consented in those all to Via half XXX,XXX in New about two-year for Project Parent The New newborns born year our program

step think the at and a cycle, and accelerated diagnostics points not the therapeutic along spectrum. a we outcomes, back moment, when siloed whole human care looking positive about Taking for we're just

that Our we health, we'll the have hopefully, the advancements the focused and continuum maternal kit, To a excited as example, more pipeline truly play our strategy such newborn and to the we newborn health. childhood screening, larger full of this years DMD for be planning into end, in family solutions in about are fetal in months from novel and today, ahead. some family on to discussing

is Turning how DAS, opportunities. new fundamentally market to our are approaching analytical new shifting we go-to-market strategy

we I to win forward. As cannabis at mentioned early is approach a conference, example replicate of new recent that this hope go-to-market an going

really XXXX. business million testing analytics efforts and in including solution, customer relatively early in Thanks progressed our end-to-end voice XXXX the nascent quality in $XX sample from and prep, and revenue workflow testing, have from capabilities. of We understand to provide to the cannabis an safety to a

past MJBizCon, now American show offer hemp to leading cannabis a technology cannabis standard this player testing and to a and that to reach, announced leader portfolio will hemp at strong commitment and Scientific continue Emerald our lab North market broaden testing to expanding rapidly we and this distribution their To our December customers.

a solutions complete our developing key in also as sciences differentiator success Our across life serving workflow portfolio. is

on With target research. we both in stage tracking and discovery identification, of ahead now example, optimization is can for deal pharma in generation Cisbio, of for solutions end-to-end and lead the biotech acquisition the our provide which preclinical model,

alone, for now technologies, kits quarter protein we several in in our consolidated biomarker new an site Cisbio at reagent and total discovery our fourth and France, PerkinElmer the reagent we innovation detection. future. the all expect phosphorylate introduced in uptick drug with Codolet, And for During screening R&D

delivers in A within market. assets life Meizheng the coming the fast-growing final of already to in labor-intensive strategy The rice into food key example XX accuracy paddy we channel is results testing take for new integrating to need food PerkinElmer our are steps There, eliminates X and also new mega reverse With some to accurate as a with rice key ever-growing and its markers. of sales quality the from serving people's demands and for the XXXX our customer staple important minutes. PaddyCheck increasing this chain. increasing advantage ensure research quality diet, solution Perten, food is global of is commercial local technology with which the introduced for One automates of of and the PC planting of breadth, expertise. helping domain intimacy example recently this to action traditional grain analysis

only was part double-digit growth were for quarter, consolidated maintained of synergies. we fourth the and pleased Meizheng While early with its

to health year: As three experience. challenges; critical the laid to will for our organization have innovating Ensuring ability we this customer a priorities on key and mindset; be to ahead, evolving look and scientific address out first our we Company our execute our across success critical employee

where tools, experiences deliver are improving customer's need how when, PerkinElmer processes, and we providing means standpoint, exceptional From with to responsiveness solutions, the our our and them. customer that

that And the markets. innovation of further culture and internally, across partnerships customers end organizations front, on offerings drives our we the year, visibility our will development before. this continue cross-company us to work On than you ever greater new with will to culture see a accelerate industry creating and

strategy. Before people workflow Earlier and across to market from a role testing month, to to and provide few next an the lab key the were has I messages that team Pittsburgh, where Specific Vanadis to the low a over we the PerkinElmer to Vanadis, hosted high will broader We discussed and for the rapidly. play NIPT to prenatal democratize sizable NGS, I over NIPT Vanadis Jamey, woman hand briefly the non- Vanadis in is investment over community customer drive a NIPT globe it on our helping tried test is in no-call decades. Pennsylvania, update precision believe Vanadis. and home we this to want at its system rate, continues the that every positive, remain truly invasive due feedback clear growing advantages pivotal genomics

terms healthy XX have In achieved systems, placements in we and of to XXXX, funnel. continue we a

on XX path up XXXX. from that would to For All XXXX, we XX systems this placements as to total, which XX the XX told, and to year, placements organization. imply year end installations XX an in are the is XXXX in in confident right our XX between I'm plan another

next sharing internal I we XXXX, of the well-positioned lot throughout PerkinElmer of chapter turn changes story. the progress our to continued a page there While are to forward now were year. the the we as in look

I'll to as hand to financial it XXXX more QX as now and over detail, XXXX well our in discuss guidance. results Jamey our

Jamey Mock

and Thanks a evening, everyone. lot good

of point which the The want is the drive been simplicity and everyone's call our to transparency Company document earnings posted section fourth goal additional quarterly Before has under attention to Information. I website this of to Financial I Investor our around start, presentation, performance. on quarter our and

served to fourth I'll on financial provide and some I quarter. end additional the Then, begin our Today, by highlighting metrics. color plan markets

outlook for back look performance XXXX. XXXX on a financial providing by finish I'll our our and Lastly,

are entering full-year with Jumping expectations in, quarter and conditions our our pleased fourth with were quarter. XXXX the performance. we in results fourth line Market

global our cannabis, doubled EUROIMMUN, at As which accelerators perform they broad-based well, led have more on grew which and all year, continued demand, to than by a year-over-year. clip double-digit growth

Pittsburgh genomics Vanadis to to momentum testing and complete to end track first remains continues the business build. Branford of by quarter Our the the on consolidation

XXXX. the the development positions by recent Vanadis Medical December was American mentioned, important in the NIPT As Vanadis Diagnostics Prahlad of an PLA for Association that granting code favorably

the and performed undoubtedly year to quarter Our XXXX incremental strong and years concluded standpoint, Solus prior Meizheng, of been to organization. organizational Cisbio, well operational well-positioned in the us made From complexity the during actions have contributors be an a acquisitions reduce ahead. all nimbler

is increased product the of accountability incremental organic margin XX% the and organization. XXXX Our transparency in across direct a

$XXX organically, acquisition XX% business, driven grew Turning X% sales, our lines. provide color and momentum food the fourth quarter and in in strength X% X% to business business. foreign revenue on of revenue exchange broad-based a net of XX% across We included our a and due headwind some to sciences representing Discovering moment. continued reported by will life a Adjusted organically additional health representing grew analytical in businesses growth sales immunodiagnostics to solutions, rebound X% diagnostics organic both I total also and X% million with X% By reproductive grew tailwind. core total a portfolio. results. our achieved

quarter. third growth a geographic organic what we trends experienced the basis, parallel On largely during

grew Americas both Europe and single mid Pacific the digits digits. single low Asia while grew

our in margins forward. we Operationally, XXX quarter, mix, driven extremely in significant we fourth pleased performance Adjusted potential to are improve the expanded profitability productivity, basis with points and operating the and see to continue timing. quarter by fourth actions some to XX.X%, cost-out moving our

XX% was As $X.XX of adjusted our fourth earnings $X.XX an of and share increase of Prahlad ahead mentioned, XXXX per of the quarter guidance. versus

our let's further drivers Looking within our the start segments, into with key diagnostics business.

remarks, revenue my XX% was both a earlier growth and low with was double geographic a led off Immunodiagnostics X%, way from mentioned organic broad-based organic basis. As ‘XX. which growth a rate, XQ strong digits. mid-teens comparison which EUROIMMUN grew product grew the in in

health a Pacific. Europe our earnings healthy expanded in the grew and U.S. driven at We low grew screening the single highlighted coverage grew both digits in expanded last call. and Geographically, Reproductive Asia over Western mid-teens organically, newborn on clip. XX% by Philippines China

XXXX. from also in Additionally, programs Japan in benefited screening expanded and we Vietnam

business automated robotics and and than quarter, quarter. soft, single genomics softness the product our in our by remained nucleic declining digits acid reagents the in offset was segments. third Paralleling NGS in extraction applied fourth high Momentum more workstation

lines. growth high to Organic and in digit life market, by and growth revenue solutions. biotech, food fourth our we of driven analytical the our pharma organic discovery in product discovery single Turning franchises. informatics experienced sciences quarter and propelled by end was X% By

continues double collaboration, and gaining amongst increasingly digits and drive solutions increased fourth Signals informatics time scientists. contract Our well, growing are quarter. PerkinElmer’s to to in perform for business top accelerate pharma, R&D research the the Signals efficiencies improved as organizations, discovery traction biotech helps

XXX% digits Asia business, digits by sequential quarter, cannabis up Pacific solutions year-over-year. were core single an in and markets up industrial the environmental Food safety applied food up over Overall, improvement in a and up in single environmental cannabis and our The driven demand. in continued mid-teens mid strength modest and grew X%. with approximately food industrial core improvement was mid

Shifting our quarter approximately $XX tax fourth rate to other expense XX%. Adjusted below-the-line items. net adjusted interest and approximately was for and the million was

$X.X debt We the and in to $XXX cash. finished quarter year quarter adjusted million. balance of $XXX billion approximately the was with cash in million flow cash Turning was and the $XXX free sheet. flow the Free of million

reminder, the due prior with is between number the adjusted payments a and As associated difference the to reported acquisitions. cash

For which free versus the an conversion adjusted year, we XXXX. flow XX%, cash achieved improvement an was of

While was estimate, we the the our understand place feel fundamental we of this years. have shortfall, to plans levers short the the right coming action of we XX% and over improve in confident the conversion rate that

the exited adjusted to a with we quarter approximately times. EBITDA debt Finally, X.X of net ratio

the to results. Turning full-year

internal of and and our relentless by progress focus pleased the entire of macro very are We external the displayed our aligning uncertainty. made times organization, our organization performance, change during we

organic growth. we X% XX% food, played out market’s year, the entering core expected revenue and consistent end for were throughout the posted we per XXXX, Except growth adjusted as conditions and share year. earnings performance For

standpoint, organic an shortfall. improved our of a which than tax beat From the benefits, adjusted slight performance offset more guide margin due EPS our by initial and strong we to midpoint $X.XX

acquisitions, millions XXXX, X% transformation X% $XX headwinds growth, acquisitions. new and over transition approximately be the to growth XXXX, accelerators, exchange from Consequently, we million foreign from contributions growth, $X.XX recent prospects revenue billion, for past and reported and the between expect few structure. billion $X.XX the organic the to our we remain including our and of to including $XX we by for excited years, of portfolio momentum As organizational given our

to foreign forecasting guidance headwind upXX% adjusted and from for including XX% a EPS We're to $X.XX, $X.XX $X.XX full-year exchange.

We by expand adjusted operating XX expect our to margin basis points.

fiscal other interest and XX% tax we from a guidance XXXX. XXX share the Embedded year. impact the for a Finally, to full-year count anticipate and rate is in this in adjusted week in XXrd million million $XX expenses, average our

Therefore, every of you As to includes similar on year week. XXrd a operates the most PerkinElmer know, XXXX, fiscal year XXX-day a calendar. fifth

$XX For the will be anticipate the approximately week of XXXX, revenue. million to we million XXrd impact of $XX

$X.XX. given However, and $X.XX the dilute operating of week XX EPS XX the negative margin extra to extra by adjusted basis our will by to week expenses, points adjusted

first For quarter. purposes, modeling extra week the the falls into

improvement We conversion during XX% anticipate which flow represent year-over-year. XXXX would the XX% to fiscal cash adjusted free year, of to X% XX% a

going way, and cash XX% to growth acutely in focused process a two improving XX% to flow to to on free a be are We get back three-year conversion balancing range. our the prudent while profitability. It's to

Turning to the first quarter of XXXX.

million, exchange $X We foreign are X% forecasting revenue representing a reported organic including revenue approximately of million of comparable headwind the $XXX versus period. growth, prior

In $X.XX. terms quarter, first guidance for are earnings per we the adjusted of forecasting share

our We from to extra quarter XX by XXX expect operating rate first week impact to points. dilute the the basis margin

mentioned in higher Excluding in earlier. first tax noted last the Again, be I fourth XX%. the quarter is foreign of X% headwind which earnings the week, and of quarter page extra rate, exchange would earnings presentation, this up our to all

it growing fronts. outbreak the a hand is multiple back I Before coronavirus to concern on operator, the

a go for thoughts control infection. help hospital impact testing. to to franchises, of develop PerkinElmer and we going of out across may think said, year. continues highlight China working lot in into first risk to are is financial embedded the and any and negatively or to could SymBio There our we this Therefore, hopefully immunology solutions given the to those guidance. in impacted. patients avoid disease infectious epidemic the not prayers this grow, it going EUROIMMUN prudent to it unknowns. First, have and currently are That Teams impact the stop our our actively If quarter full-year spread

open prepared to the This call Operator, we would remarks. this time, like questions. concludes to at my

Operator

And Schulte Instructions] from question first with comes Baird. Catherine our [Operator

Catherine Schulte

that for government back first saw shutdown in just go fairly we Hey, having the X%, guys. extra to out Thanks to guide. I week, we the back questions. wanted the year. to the with quarter quarter comp think to X.X% a closer last first If despite easy comes I

walk just quarter? us rate off look what minuses think you of a like you growth pluses first the in could and So, normalized that through should

Jamey Mock

Yes. this Thanks, I'll take one. Catherine.

the if we down it's like week, you out extra versus think, is back quarter X.X% the quarter, every year more reported organic X% the X% So, everything to XXXX which growth. first -- in in I

throughout year. So, comp similar it's a the

two affecting there's think, that in us the largely things I quarter. are first

genomic is testing. First

we If high, of started very XXXX, off you remember sequencing in particularly part business. the that

And so great first second little had the consolidation. to half a half a due that and bit softer

point that half continue itself, growth to first so We quarter, by a here. quarter the organic into what in probably planning expect that we're on of the first

had weaker robotics applied automated to first is area Similarly, that that half a we're continue on when and I half, expecting half, genomics. the stronger second the workstations And first into second mentioned here.

the the two difference really first things walking saw between that and fourth run those quarter so, And throughout our the organic we including the rate here. year, only are X% into quarter

Catherine Schulte

genomics that on exposure headwinds that I continue DTC some year. have points data microarray know a meaningful will applied there. suggesting to you this number And some we've Okay. of industry business, seen have

So, how to returning do that you business better think growth? about

Prahlad Singh

this Catherine, Prahlad. is Yes.

QX the going think as our screening relationships of The thing market on we're is not and that to that resolved. I side. the DTC through So, out we we the earlier, there is much. are the that exposure by -- piece should pointed consolidation Most pharma just our be end newborn of

exposure we is see DTC So, don't that too we, to not -- much. point, as don't at our this

Operator

with next Dan Stifel. Our question Arias comes from

line is open. Your

Dan Arias

sort it we thinking about that And have revenues still there. it the talk of and on kind placements along Is will for there volume the a is touched Vanadis yield just of about this were you like? point, you will out just that or lines, confident there? just in labs think the you utilization what will you then that XXXX? the on Maybe fluid you can of and are Prahlad since kind trajectory you those to terms of feel visibility at that ramp look when get What

Prahlad Singh

a in of actually Dan, of are in as in Yes. installing fact, we currently systems. the the process heavy matter we shipping and a fact, very several funnel have -- and

and As that continues now our we have said be flawless the a right adopters have I is, earlier experience. to focus earlier

XX XXXX. installations, look the I in XX to to earlier, just in systems XX XX We XXXX systems range in XXXX, placed you XX and at If pointed out between what Dan. XX implied

So, from are said, the But, track as democratize important goal in metric early lifecycle. our the in on perspective, eventually to we product’s think NIPT. installations end, to an is our I've Vanadis

So, focusing. that's in are PLA with issued. the code, U.S., And also where NIPT gives is the once us several we that that advantages

priority on from So, code. the the working we looking a the number installations, out data getting perspective, and at are clinical of PLA

Dan Arias

Okay.

it a forecast like that's on for So, TBD sounds the Vanadis?

Prahlad Singh

Yes.

from our number revenue a continue monitor think of guidance will installations. I perspective, to be the to

Dan Arias

then little had year, and I if Okay. think line which from then, and year end organic from secondly, organizational one-off out a at Jamey, or the elements. is the that you a also And XXXX, where unlikely And bit just think week, either half the of or with be some midpoint, point juice this getting the extra at you X% Meizheng. is the repeat should that's about issues, guide, just in which maybe to I I so top-line getting take then, somewhat of you're

something underappreciated side are that's on guess, for either play So, XXXX factors conservatism year in versus the about that maybe of DX is the at ramp the or outlook I start to DAS? much organic the the how

Jamey Mock

Yes, good question.

here, the kind mean, talked we maybe just markets I through So, Dan. end of

a immunodiagnostics. of I and around caution we bit say have So, is sciences little incremental life would where

think saying them have So, been immunodiagnostics. pretty model time. some leads But, for we're growth. XX% Obviously, mid-teens way consistent I we're organic in the at that to EUROIMMUN quite They going it’s there.

downtick So, of I we expect think a there. little bit

strong. Life sciences, we've but anything, have seen think I don't remained very funding levels

And probably the so, downside upside. but I'd we're say than is hopeful that it more continues, there there's

core cautionary. look fourth point we that, we and large of you in what as food So, quarter, had terms least some the some in here contributor if Offsetting applied that's incremental this should about upside. and is anticipate where don't rebound of we're year. and Conversely, in the I’d data at at say, I one talked genomics, cannabis food provide kind being

that kind So, through of those there. bit but once has well of year applied genomics, half we'll little get then the the competition -- a how And little offset comp first in here. see easier it's a we bit this half, as going, hopefully second

cautious your maybe in and steady. So, pretty overall, immunodiagnostics, to a life others food bit applied little question, answer probably genomics, little bit sciences, the in upside a

Operator

Our DeBruin of comes Derik from America. Bank question with next

is line open. Your

Derik DeBruin

So, of a couple questions.

one, as customers have they the some think, I I think much some companies didn't during prior of but companies, -- in flagging budget were flush a fourth here, did maybe years. the but the think I don't first some exposure as expect you quarter significant from that

So, sort you of what I'm just like and just what in activity. spending the terms saw wondering incremental of budget sort year-end of was

Jamey Mock

always don't tell, Derik, difficult but to It's I think saw Yes. we much.

Americas In there of quarter. in soft the the the quarter. markets fourth Applied a in actually in little hung it sciences, life in was fourth terms

So, here. it's off out But I’d to maybe difficult the there. there's and overall little a bit tell ordinary nothing of say,

Derik DeBruin

you questions disease And do on Okay. the testing comments just infectious I business that that have getting coronavirus. some the been appreciate given an the on today, you've We've got. just China,

wondering, are the to are headwinds [ph] for incremental people to you of you going potentially potentially you referring you testing products headway into are think, offset sales some would it, to see any to? I were -- diagnostics your

Prahlad Singh

maybe And I'll Yes. take that.

make CFDA, we process developing assay. say an us Again, I So, we and is it and are What's for assay sure with frontline more outbreak, the unknown. at But, to are an which entities assay impact testing. we is it point in making the have strides. that, we doing a NMPA an during they And a just the get to right process. approval with we of focus PCR now working is have testing through of frontline the would this several Derik, can that most do that of to out. assay the commercial from a now generally is use other perspective, antibody are the take and PCR CSR a

Derik DeBruin

Jamey, can more squeeze And if I one in.

a number you that basis? there if mean, basis XXXX. that is margin a I expansion in of guess, week, XXX, -- points of extra sort the about I mean, XXX points So, sustainable like adjust basis implied XXX op is how operating I there at you're on I there go-forward a that Is years put mean, to is percent -- targets few margin number? XXish your you ago. upside out of incremental sort

Jamey Mock

Yes. in I a XXX. coming be we've We healthy was mean, guided clip that in To off extra a we XXX much week expansion done beating pretty been year I can the XXXX. XXX room XXX XXXX think, the ex And getting up XXX for at and here. like we basis think mean, don't saying, profitability points that is over see and stopping point, up lot your ended in XXXX? see the continued into ever mid-XXs. We of How I ultimately XX% time point. to

upside XX But, programs in there basis to to we're mid-XXs. focused long I could get more to putting and Sure. guiding? term So, place this points on be the think the that we're

Operator

Thank with ISI. Evercore comes you. next Kumar Vijay our from question And

line is Your open.

Vijay Kumar

would could be margins revenues, on extra like week you touch question. would revenues why thought the I Extra down? margins? can I Jamey, the walk benefited margin just if us, incremental have what

Jamey Mock

Yes.

the You’re Vijay, for the talking year? quarter, for or

Vijay Kumar

incremental margins? why have Quarter revenues lower and for I’m curious year; just the

Jamey Mock

Yes.

this look numbers. earnings Vijay, exact to in and So, we the the presentation, tried lay our you -- out at if

amount if coming into we that to revenue it divide by feel revenue, extra So, we $XX will year. additional our But, just right which total experienced, XX is that's XX million of the you we the like not what weeks. extra and year think week provide the of take

However, week, if than next offset of for that expenses an gross margin. at you the amount look that more

Like that year if tried get gross the extra to dilutive take of for last the operating expenses actually of we you margin, you add it's in the interest said, you an year. and to quarter an to roughly earnings for both page lay XX XX% and week that then extra week $XX the million, expense, I So, presentation. out, on thereabout

Vijay Kumar

week, One Europe? And Vanadis, related for on tenders a to math. compete position then, extra is just the did if follow-up or are they And week maybe it there Shouldn't is you in $XX guys as? points than be Got on what basis that the something to -- extra week implied million sub higher extra million you. on XX XX, on a to in $XX theme, just the the topline. that -- you

Jamey Mock

going start the with me Vanadis Let in jump then and extra here. Prahlad week is on to

fall So, on days calendar we in to they this back saw this our year look think at January if actually customers, and where we so, of most And operate a you XXst. XXXX, extra year, the fall, Xst in December in the fringes.

the going revenue this XXXX quarter, the fiscal we recorded was therefore and that spent is revenue. mostly this to from XXXX in take So, in year fall and that XXXX, but for example. December think XXst XXst our for in actually be XXXX

professional days. that some let's down And back you services. once that you to, days, lot those out of is scheduled CapEx, is So, say couple more a get of of X a

So, just rate. run daily not a

impact down X%, you which are of range, we ends And therefore, being said recurring -- to X% organic believe up that that we to XX% which third was to revenues so, some for XX% quarter growth. get the it XXXX, the our was X.X% actually in to very

here. So, a similar assumption it’s kind operating of

Prahlad Singh

Europe. the starting in Vijay, tenders part question, participate can we for and are to in yes, of first your

Vijay Kumar

has clear, just the around on potential guidance any in Europe no wins Prahlad. assumptions helpful, to Vanadis? That's be And

Prahlad Singh

Well, are I what we assuming think, basically XX is to installations. XX

some and some is Europe, in in of is is Asia it the So, some in U.S.

Vijay, we on of wouldn't we which tender, particular win. We which focusing not are sort win could or

Jamey Mock

CapEx But, as there be guidance as some as in our sample well. revenue some well will ramp year

Operator

Thank you.

comes Steve Our Wolfe question with from next Beuchaw Research.

Your is open. line

Steve Beuchaw

time your XXXX I particularly a unpack process thought headwind first, for reproductive Thanks guidance. around were was Hi. in could in the the you XXXX. Good here. there afternoon. hoping Birthrates in China

you you dynamic And category? the about for birthrate expect broader thinking growth in prospectively? do that are what So,

Jamey Mock

Yes.

a up bit. ticks I think, reproductive health overall, little we think

we've So, kick continued issues, kick We genomics in that some, anticipating that in reported significant to in news I -- any we've gets that in should see we think there got some. are on particularly birthrates. Vanadis not should don't testing good China.

We expect that to continue.

a the remarks have Vietnam. earlier in mentioned prepared expansion Japan and of I and that We Philippines lot my around APAC good

a little pressure. that So, has

there planning where little birthrates probably expansion we'll and to upside But, health year-over-year. geographic net-net, So, us. is bit reproductive see definitely gets us, of we're impacting a on

Steve Beuchaw

I with minute for just even Okay. cannabis. bend. wonder And about then, you speak but not a a medium term for maybe XXXX, if could

the XXXX growth impact numbers around a XXXX. that XXXX? put Can in you be or market a be smaller cannabis matured, that, is is any expect for Why just is slower than you that? Thanks. growth there somewhat And mentioned would after to dynamic? competitive big You was that in it somewhat

Jamey Mock

thrilled the to mentioned I bring. Pralhad are $XX contributor we cannabis it a we base. Yes. this off performed which revenue, incremental was not year We're guidance. And extremely that kind is on that was in $XX banking of million mean, the that well. in difficult with team, predict. million solution this That

not. like that's but up but We not to It at another still we're up go to right feels expect assumption it happen, banking just a $XX now. planning on significant rate, that what a we're go million double-digit could

seems great. still it while. market the So, how states a see We'll for

contributor going there's couple But, on I of bank line to that don't think on in kind come XXXX. I year. this think more that'll we're incremental

Operator

you. Thank

with JP Peterson Morgan. Tycho from comes question next Our

Your line open. is

Tycho Peterson

thanks. Hey,

to backing I guide. least grown efforts, to you the the week Sorry with $X.XX. you you X% the able have would guide have to at to would thought $X.XX to consensus. guess mentioned XQ been reorganization XX%, below extra consensus. That's still out have would go back to recent But,

So, on EPS are extra talk there other weighing that offsets week the if other can quarter? kind you are than about of the in first

Jamey Mock

-- I Yes. Tycho. mean, hey,

up as year. and So, in probably we investments little general, Vanadis bit of timing the little comp in terms accelerators growth of in a set we're of et There's line. our margin cannabis, of last to operating cetera mix the well as in year-over-year, some gross as versus kind making on of as exited on the line a the what kind year there margin well the is of end difference bit

overall, throughout excluding that the basis here. think And the the extra be So, points we'd in quarter, continues about year we week. the up uptick XX

Tycho Peterson

of like customer Was there it installed XX last the saying did now it down? And why quarter return down, went sounds It couple a did or something, then, you're Vanadis Okay. quick go the was clean-ups. XX. base and

Prahlad Singh

it's XX. Tycho,

of So, till XX, end the XX. we the were third quarter, that went and to

Jamey Mock

Maybe, to Tycho, XX delivered we XXXX, systems. XX. XX saying were XXXX, in get was we what added systems to In we

to we're in XX somewhere year, guiding Next the XX.

out increase every year be these we’re approach taking systems. we on placements prudent how So, methodical our roll a to and

Tycho Peterson

to then, was the maybe mid-teens overshoot to XX%. And on What quarter should right. us comment allowed -- made in thinking not that XX% there to a EUROIMMUN, fourth that's in be something you sustainable the the quarter, All that upside? maybe we and back fourth

Jamey Mock

mean, No, we look, no. I mid-teens. hope it's that

having family, of I two both first saying think, it's mid-teens PerkinElmer at consistent year we've going initial years EUROIMMUN does it a Throughout the what model. planned years, the in XX% we're That's forward. budget been maybe deal again. that in we in grown to going

this operating about consistent And like think So, we've assumption. at the product terrific is plan good based upon always a to introductions, geographic XX%, including XX% saying, U.S. just in been expansion, we we'd

Tycho Peterson

And Okay. recapture expectation to It line of in quarter. like with one first one in genomics, Was you original that most quick of you're just in going the the fourth the then, were that recapture automation. quarter? the on sounds expecting half your to or last it

Jamey Mock

the persist that we're to No, expecting not quarter. as much. Actually, first Tycho, into

half, second second operating assumption first If get growth some We the in year. change the to a the that you here continue first on will of the that, to persist. XXXX, it's is we're in Naturally, of you from on we're that banking different in push comp. rates half second of things we half happy. with the expecting going saw the into to perspective, our of the when XXXX. the half not XXXX saw a now, that But half demand keep right right than get to better and we're So, pressure we're seeing we

Operator

And with question Patrick Donnelly our Citi. from next comes

open. is line Your

Patrick Donnelly

Maybe kind the volume? us the color on on Can growth give what of question looks then, that day just on volume And some like building is just maybe sensitive on talk China business to how just there? through the Tycho's EUROIMMUN. per hospital you

Prahlad Singh

per think Yes. Patrick, a day. I give it'll be to difficult volume

given right we're coronavirus in thing. out Jamey I the all evolving situation the his highlighting think, remarks, doing as pointed now, is

depends You It will of all that out don't plays know what be. the over the weeks. impact on how it days next few or

Jamey which From we years. do at the been the we modeled it perspective, forecasted question we point is have what over deal XX% that that I that to that model, earlier forecasting think, past in hope And than Tycho's continues has done couple way. of it our have the XX%. EUROIMMUN to made better has

Patrick Donnelly

some Jamey, XX% And and guidance. initiatives focused inventory, appreciate in you're some out on just agreement points? talk Okay. focus I know Can then, guys talk you maybe headwinds the XXXX about the to some the flow, of conversion the expecting trends Can internal are XX% receivables I you there? you around terms. about extended you kind had on just there, cash

Jamey Mock

Yes, sure. Thanks, Patrick.

flow we've learned some not headwind. go reducing but about we cash The to capital a basically our are made of we've turns lot progress, last assumption mean, here. years, definitely I where been it where been over So, the static, it's that turns, we've some uptick. And wanted to, is couple actually the and working XXXX working last a operating capital unlike year

you really, a collection like and But expect of different it's emerging ago. more and basis, on to somewhat plateau there's we we've billing in some and at subscriptions when much invoice receivables, markets some four started et developed three particularly are accuracy So, cetera. around now. the of processes models. seen internal changing, a in And things in business Informatics, years to efforts, and that We've couple three-year or sell timeliness look that terms China XXXX.

So, we little been should into bit a that. Cannabis, some cash here. expect from leaning more we've

an which we'll the drive there's great. certainly over upside. fundamental is -- the in this Hopefully, couple next static embedded years, to standpoint, from efficiency be will And basically XX% XX% So, that.

The second thing I'd say is around capital expenditures.

I extremely we're business So, expansion. Tulip then, That's of lot some would But investments require some years, couple and didn't of EUROIMMUN to capital year. China; EUROIMMUN. remaining think see over two a India are there. been our genomics, the space We we've of building we facility of this there well. in about a after I capital And And facilities of downtick think capital out next the the growing increase say expansion. is that, we’ve that there. got expenditures in I don't kind monitoring repeat XX% areas in

static bit it here. a kind be And while. So, reduced we've downticks then, little for of It'll that little a over time. hopefully,

Operator

next our comes Cowen. question And with from Schenkel Doug

Your open. line is

Doug Schenkel

much just I'm queue ask into three the want just to going the I don't get And to because noise. quick and too train. I’m back [ph] on then background ones, have

you you. to mix the priorities are Patrick’s And capital comp target deploy? on for guidance embedded relates any by change up you repurchases following a Do formal conversion? is M&A? as year? it year? first, for and assumptions the to share for what to or there So there for your been has growth revenue are what And into Second, three, capital you of free between what’s cash question, have expect geography plan Thank growth incentive intend flow the terms deployment in

Jamey Mock

sure. Yes,

and answer to ask the I then second but two other I'll that Doug. one, you didn't So, catch one, the repeat

is now cash comp or now incentive our in our free in cash of all comp plans. plans. financial Free incentive is -- sorry, So, flow

that question. answers that So,

we continue to a priority From standpoint. remain a from capital perspective, acquisition deployment first

four of ‘XX. did if look And four in acquisitions at think, the ‘XX, in I We a look at always healthy couple years, we so, acquisitions pipeline. last you

down to liquidity of the our amount but that's much I can pretty think and be ended a after refinancing. end been still priority expect The versus I where, stronger a And leverage dollar year is it's last always terms We deployment. our in you here us fluctuate, active might think, there. consistent. from then, capital bit little

I it. think, life diagnostics and that's And sciences. primarily we're focused think on I

out you the What question? question And on cut the was second Doug. second there,

Doug Schenkel

Yes.

for in for revenue terms of are about that, what you year? growth embedded assumptions growth What the guidance Sorry into geography, Jamey. your by

Jamey Mock

Yes. Good question.

board. we're basically, mid-single-digit across the So, much pretty

all Americas was If at you APAC, that's XXXX. and mid-single-digits low-single-digits. look been Europe

the maybe over call We that I a expect clip the kind to into reign, revenue mid-single-digits. Vanadis mid-single-digits weaker of it

consistent So, what pretty saw with we board consistent across and XXXX. the pretty in

Operator

question next Jack from comes with Our Barclays. Meehan

line Your open. is

Jack Meehan

in maybe current wanted of curious progression? guidance of your fourth terms seeing to what start, the in And back you're just I there state to the the DAS. that grew what from quarter. the was macro, industrial customers, I move what XXXX given assumes

Prahlad Singh

start about I So, talk think, XQ to Jamey. with,

Jamey Mock

most where year, been consistent with Jack. it's Yes. flat, of was XQ the

Jack Meehan

And for XXXX? then,

Jamey Mock

for environmental operating flat I the our We assumption year. expect been no think consistent And remarkably change. XXXX. pretty that's Industrial throughout entire into has us, going

Jack Meehan

XXXX? there, contribution? pace I back market. just wanted well? up on business, additional to guidance there diagnostics timing first lab, on of as for then, What for assume any What And does quarter the the the testing assuming contribution dynamic was is the the genetic the the XXXX marking the And follow given final for transition,

Jamey Mock

Yes.

the So, extremely second half a first million in did the total. in half; XXXX well. it testing under was it stronger than genomics $XX much little Obviously, was probably

the that the the be in the it right going mentioned here, take good XXXX, the terms to because three I happening but is substantially. of earlier that think the I expect you till that to guidance real challenged, my or and feel road specific in remarks to supposed there through it, continue now, not onboard And, terms We sometimes it's cadence is people the year, rather space. consolidation -- not about happen block two well, grow it’s but to give of will In quarter we'd can first in can months hiring.

ramp the we'll again. feel up And to back like so, quarter second is we when start

from another genomics expect And healthy in XXXX. driver incremental we testing so overall, growth

Jack Meehan

for. If what there higher one Was individual bit than outsized little the a in looking Meizheng that from DAS in The contributed squeeze was Great. growth more, contributions quarter? we could acquired anything the I Cisbio? were what and in

Jamey Mock

both no. and Meizheng to not continued do well. Cisbio really, No,

has perform said digit from year. think, something all growing got double out and it We weeks I of has continues XX well. And plus to Meizheng the or we in range XX% I the into quarter them. Cisbio been think XX been

Operator

you. Thank

Jefferies. with Brandon from comes next Couillard question Our

is open. line Your

Brandon Couillard

in Hey, third on business just some the restructuring for was curious you minute. if did services I the Prahlad. could touch I you know there a quarter.

what specifically curious OneSource into XX? the business, as your is services for outlook look Just enterprise

Prahlad Singh

Brendan. Yes,

restructuring, did I some business, seen. think, in of you’ve with was terms services again This as of we the implementation the ServiceMax.

coming to continued of see there. sort out of productivity We

high are look win we some for forward, digit growth as think, business will and we think, be we for position expect as us. single said, continue to in And a I XXXX, it a you to I good tenders.

Brandon Couillard

rate specific up for tax behind I year. And for just one the little Is of level the tax a sort that conservatism added or embedded Jamey of anything on rate? this ticking see. there just bit

Jamey Mock

Yes. in the It had gotten at XX%. XX% year, about XX% good question, XXXX. We No. guided and Brandon. for to down in It’s came

So, there is in a little natural uptick tax.

growing, I look we areas at Enterprise, those at jurisdictions. think, EUROIMMUN, tax you if you are are of a look at where lot you higher Informatics,

think We items. forecast So, pressure planning right had that some anticipate the a go number. upward the XX% little therefore, are XXXX, we there is tax XX% do is that that offset items, in But a a we makes to natural And down us to that have lot of brought then, which to which to up XX%. the difficult us there is little. from basically the discrete always

Operator

Thank you.

next comes Wells Our from question Leonard Dan with Fargo.

Your line is open.

Dan Leonard

have, some product are build XXXX and have these organization? with couple - us potential in points efforts as teased Are the or or impact A things. of would combined things service or these be in you would XXXX what whether an a result further introductions have they in new efforts are a these things that beyond? of you. of Thank that One, and Prahlad, coming XXXX proof impact the

Prahlad Singh

with benefits other business. life the as that combined we been cannabis think, solutions sciences have our sample our out There we’ve whole of sides from reagents where we have pointed the seeing some the examples already, seen. business from I workflow I applied prep genomics started of

to we've So, this. And think continue out be to synergistic expect opportunities proof to ongoing. I of discreet it's more going of this. started It will a we don't seeing points to be item. see coming XXXX And

Dan Leonard

-- getting coverage to you for code the me And go walk can secondly, in strategy to Okay. your that walk policies you mentioned through from included that PLA PLA NIPT? go from through to then, strategies medical code your you Can code.

Prahlad Singh

direct I us hopefully and And methodology just And specific advantage a that can we the on additionally, bill reimbursement billing offers can that we laboratories. incorrect offers negotiate also insurance any that as getting with think, coding. rates manufacturer the NIPT. peers rate a would of directly to reimbursement code Vanadis better the be for risk without

given of just that the that's code PLA in we say level acceptance that I ensure our hand. hands that So, December. would really at what want came we're right competitive all end is code are And of the share point commercial the the get the we get on think, in But at now, time and to submissions I in to I and situations really reasons. for excited this about EMA's

Dan Leonard

it for final that? the APAC Jamey. of China what And clean-up or was just Thank mid-single-digits then or Okay. rate lower Jamey, it than higher was consistent Was with growth QX? in you. the

Jamey Mock

with Consistent Dan. APAC,

Dan Leonard

Thank you.

Jamey Mock

problem. No

Operator

And Montgomery. Thank a Janney have you. Knight question Paul we from with

open. is Your line

Paul Knight

to like goal there I any than that the you you product areas year? you food cannabis Thanks for the point are what revenue, benefited Is to time. and know the the have or from Is portfolio has would clearly want R&D it further? this and faster increasing would of safety testing. the spend on some develop

Jamey Mock

a little look that to up efficiency, over related R&D we Overall, of time. little if to ticking bit Paul. was a at some the restructuring. bit Yes, that it organizational and be saw actually in of you We XXXX, want

this embedded what's a if a a of in little maybe anything, guidance percent as kind of constant of is so, sales, uptick. R&D And bit

between, flat, and bit of a a think can one in revenue little budgets. And as food. areas we're the sciences, least and behind not cannabis that increasing some that's you up this mentioned be little expect food, bit putting our we're R&D of year. percent that You resources And at general, diagnostics a will if I of think I more life

Operator

you. Thank

comes question UBS. next with from Brennan Dan Our

open. line Your is

Dan Brennan

questions. the for Thanks Great.

you you XXXX guidance you I or on that broke know biopharma, little if of I this outlook? maybe Jamey bit in baked food And So, what's Kind both what's out touched were know solid is environment. for can baked Prahlad, down kind a within in just wondering and But break don't forward quarter. the then, what’s DAS, exactly -- where for guys client and going in overall. of

Jamey Mock

Yes.

I a think And we're maybe or a optimistic that point that point here. half. it's upticks

as of to good core I expect rebound quarter if Obviously, mean, and else, in a some some here. look we that'll predict what to then rebound. much food on. we're we're But it will up you that point. cannabis climate than incremental be that was If ticks expecting comp And I food. change. that food, good little think not difficult slight mentioned I contributors. us, But bit. there's have core a impacts at that offset planning nothing should weather net-net, If I mentioned it's data though a earlier. different Fourth kind food

We tenders Life some extra and an about, our a extra sciences, week about here. I up think Prahlad enterprise some ticked talked bit. going and of business little talked well

double I digits think, Cisbio strong, and high year. in digit them this single the both We're Informatics planning were continues more to range. be extremely

seen digit. just to them So, that’s double something we're at anything. haven't But plan going

little upticks bit. a And probably planning environmental, net-net, we then, and that industrial So, flat. are

no So, change from XXXX.

and of improvement bit a uptick life make probably we DAS a in So, food, we bit year-over-year. little in if sciences little

Dan Brennan

maybe bit. ago, of obviously that with high very have of all pull kind digit like constructive or scope of guys I still you you growth the single a conversation the And you’ve you. Thank business think had changes. Thank kind you you of or would the that upside know a sound out if the then, on portfolio, Great. which you different XXXX is type little there back year on in? momentum you. balance, call so color the lot what the And the swing downside, conservatism a on But, be? But, a businesses. X% about guide, of or when you a how the would characterize given was factor

Prahlad Singh

got that of Yes. fans portfolio a for in We've the excited have Dan, I accelerating again, lot and profitable we the the continue about think, prospects fire. to growth. look, we very be

we the uncertainties coronavirus. I given example the balanced, there that think, that with Jamey talked And see. be about year, as to are coming trying we some again, entering just are in

But, will important that factors role forward. how don't growth the a the You know essentially, swing look we that out. have inherently play that accelerators very are as we plays

Operator

Thank you.

Quirk We have Piper Sandler. question a Bill with from

Your line is open.

Bill Quirk

Great, evening, thanks. everybody. Good

of So couple a for questions me.

With appreciate geography really diagnostics any and then, last there just customer staying of assay secondly, place program in some Pralhad, of I or moment. just standpoint. able test the for type, CDC particular that, procedures do -- maybe are on off, affected at development, any Vanadis to Is similar familiar to the where or outsized all the type be regulatory aware terms success seeing guess First you from rapidly Are a commentary. any placements? has emergency a the to coronavirus of question respect you're Thanks. a in of disseminate And interest in other countries? you

Prahlad Singh

Yes.

Vanadis. around question your with first Just starting

interest seeing we the perspective, interest in yet, to three an we through interest the clinical going ex-China, given that we a in from are did it. approval see spread all that we in course, we of with regions. launch U.S., recent China think, continue APAC, don't and, the the are have I Europe, broad in In on

that In they few get emergency weeks. regards in a working the the place to a in we're hopefully have them NMPA and also with CDC, your yes, and processes test similar to has China accelerated out, CFDA in second to question,

Operator

we America. Derik And from question have of you. with Thank Bank DeBruin a

Derik DeBruin

Hey. Great. Thanks for follow-up. taking a

I investors. questions of wanted from I since clarify, question. one just to Just got a bunch

when So, extra revenue growth typically, for thumb, a you days, about organic of rule companies. is X.X% the consumable look contribution at is a revenue

in to Did make terms that week. to mix? fourth like of the bit have contribution hear I your of sure million extra into a you $XX number seems was you that business the I would on it lower forward little the is, trying quarter? in just pulled it's just I'm than million to because white a say revenue thought in correctly So, $XX some saying seems thought

Jamey Mock

to X%. it's Overall, Yes. X.X%

X, guess a a thumb off So, times only I really, rule half X.X% the of X% of we’re here. X.X% to

December nor yes, at XQ rule every So, probably it's a I the done and any -- mean, calendar saw the did I execute I think years. at force than I budget XXth. other thumb those And too what if don't we've says than and like XXst, looks CapEx think that look customers December different you overall. 'XX spending most of year, let's much I different operate on our we and in before XXth sales say what that's think don't most that in

fringes here. So, I the think pretty much it's noise around

Operator

There you. like to turn no at other closing the Singh I'd Thank queue. call to for remarks. the Prahlad questions are back any

Prahlad Singh

you your all questions. Thank for

today, for forward shared on and have of continue our our as environment. updating number of the opportunities I we you. betterment the drive to continued the we’ve we towards mission XXXX. As a Thank on in to exciting progress outcomes and accelerate horizon, look you people

Operator

you call. for Ladies conference this and today's Thank participating. gentlemen, concludes

now disconnect. may a Everyone, day. You have great

Revvity (RVTY) 27 Jan 202019 Q4 Earnings call transcript